tbuckley/cabot-search huggingface dataset:
Abstract 15880: Angiopoietin 2, a Pro-inflammatory Protein, is Associated With Major Adverse Cardiovascular Events in Patients With Peripheral Arterial Disease
Authors: Carsten Thilo Herz, Clemens Hoebaus, Florian Obendorf, Gerfried Pesau, Renate Koppensteiner, Gerit Schernthaner
Journal: Circulation (2015)

Introduction: Angiopoietin 2 (ANG2) is a pro-inflammatory protein which is elevated in several inflammatory conditions and associated with increased morbidity and mortality. Hypothesis: ANG2 is associated with the composite of death, non-fatal myocardial infarction and non-fatal stroke (MACE) in patients with peripheral arterial disease (PAD). Methods: We measured serum ANG2 levels at baseline in 363 consecutive PAD patients with using multiplex bead array technology. Follow-up was five years. In Cox regression, confounding was evaluated by examining the relative change in coefficients (delta-beta) for ANG2 after the omission of the respective potential confounder from the fully adjusted model. Significant Confounding was defined as a delta-beta &gt; 10%. Results: Using receiver operating characteristics, ANG2 exhibited an area under the curve of 0.6 (95%CI: 0.522 - 0.678) for the proper discrimination between MACE and non-events. A cut-off of 3.74 ng/ml resulted in the highest possible combination of specifity (57.5%) and sensitivity (63.3%) leading to an unadjusted hazard ratio (HR) of 2.17 (95%CI: 1.28 - 3.67) in Cox regression (p=0.004). Adjusting for age, sex, diabetes, systolic blood pressure, smoking status and renal function lead to a HR of 1.89 (95%CI: 1.11 - 3.24) for ANG2 &gt;3.74 ng/ml (p=0.020). The additional adjustment for c-reactive protein (CRP) resulted in a no more significant HR of 1.68 (95%CI: 0.97 - 2.92)for high ANG2 (p=0.067). Diabetes and CRP, both significant predictors of MACE in our cohort, proved to be significant confounders with concomitant delta-betas of 19.7% and 22.9%, respectively. Conclusions: We are the first to demonstrate that elevated ANG2 levels are interrelated with MACE in patients with PAD. Inflammation and glucose hemostasis seem to influence this association.
Severe degenerative joint disease. Mild and moderately severe hemophilia A
Authors: G. S. Gilchrist
Journal: JAMA (1977)

Severe degenerative joint disease developed in three adults with mild to moderately severe hemophilia A, as judged by the clinical course and by levels of factor VIII coagulant. Bilateral total hip arthroplasty was required in one patient, unilateral hip arthroplasty in the second, and a recommendation for bilateral knee replacement in the third. The pathogenesis of the arthropathy may be multifactorial and the result of repeated joint hemorrhage that remains unrecognized and inadequately treated. These observations suggest the need for more careful monitoring of patients who have relatively mild hemophilia. (<i>JAMA</i>238:2383-2385, 1977)
Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).
Authors: Do-Youn Oh, Jaffer A. Ajani, Yung-Jue Bang, Hyun Cheol Chung, Jill Lacy, Jeeyun Lee, Teresa Macarulla, Gulam Abbas Manji, Eileen Mary O'Reilly, Simon Allen, Nedal Jaffer Abdulla Al-Sakaff, Hila Barak, Jilpa Patel, Jan Peter Pintoffl, Colby Shemesh, Wei Zhang, Xiaosong Zhang, Ian Chau
Journal: Journal of Clinical Oncology (2020)

712 Background: The MORPHEUS platform comprises multiple Ph Ib/II trials to identify early efficacy signals and safety of treatment (tx) combinations across cancers. Due to the immune-mediated effects of BL-8040, a high-affinity antagonist for CXCR4, it was tested with atezo (anti-PD-L1) in pts with advanced/metastatic (m) PDAC and GC. Methods: In 2 separate randomized trials, pts with mPDAC or advanced/mGC who progressed on 1L chemo received either atezo + BL-8040 (BL-8040 1.25 mg/kg SC D1-5, then BL-8040 1.25 mg/kg SC TIW + atezo 1200 mg IV Q3W) or control tx (M-PDAC: mFOLFOX-6 or gemcitabine + nab-paclitaxel; M-GC: paclitaxel + ramucirumab). Primary endpoints were investigator-assessed ORR per RECIST 1.1 and safety. Results: Efficacy from evaluable pts followed for ≥18 wks in M-PDAC and ≥8 wks in M-GC is summarized in the table; 24-wk M-GC data will be presented. There were 15 safety-evaluable pts in each M-PDAC arm, as well as 13 in the atezo + BL-8040 and 12 in the control arm of M-GC. Gr 3-5 AEs were seen in 47% of pts on atezo + BL-8040 and 67% on control in M-PDAC, and 77% on atezo + BL-8040 and 67% on control in M-GC. Tx-related SAEs in M-PDAC occurred in 7% of pts on atezo + BL-8040 and 20% on control, and in M-GC, in 8% of pts on control. No Gr 5 AEs occurred in atezo + BL-8040 arms. Tx-related AEs led to 7% and 8% of pts discontinuing tx in the M-PDAC and M-GC control arms, respectively, and 15% discontinuing BL-8040 in M-GC due to Gr 3 injection-related reactions. Biomarker and PK data will be presented. Conclusions: Atezo + BL-8040 had limited efficacy for PDAC or GC. Tx-related AEs with atezo + BL-8040 were consistent with each agent’s known safety profile. Clinical trial information: NCT03281369; NCT03193190 . [Table: see text]
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.
Journal: Journal of Clinical Oncology (1992)

To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU.Between March 1981 and November 1985, 210 patients were randomized by Gastrointestinal Tumor Study Group (GITSG) investigators. Subsequent to randomization, 11 (5%) patients (six treated with 5-FU and MeCCNU; five with escalating 5-FU) were found to be ineligible and are excluded from survival analyses.About half the patients on each of the two treatment arms experienced at least one episode of severe or worse toxicity, and there was one treatment-related death on each arm. No episodes of leukemia have been reported. Median follow-up time for surviving patients is 5.8 years, and 3-year follow-up is available for all but five surviving patients. Recurrent disease has been reported in 54% (51 of 95) of 5-FU- and MeCCNU-treated patients compared with 43% (45 of 104) of escalating 5-FU-treated patients. Probability of 3-year disease-free survival for the two treatment cohorts is 54% and 68%, respectively. Ninety-one deaths have occurred: 46% (44 of 95) of 5-FU- and MeCCNU-treated patients and 45% (47 of 104) of escalating 5-FU-treated patients. Three-year postsurgery survival probabilities are 66% and 75%.Substantial differences in survival or recurrence results between the two study arms are unlikely to be observed. We conclude that MeCCNU is not an essential component of effective postoperative combined modality treatment of adjuvant rectal cancer.
Bracing Those Knees: How Effective?
Authors: Virginia S. Cowart
Journal: JAMA (1990)

ATTEMPTING to prevent knee injuries, many athletes wear what they hope is a prophylactic knee brace. This is especially true in football, where the knee is the most frequent site of injury and the medial collateral the ligament most often injured. However, Eric D. Zemper, PhD, of the Exercise Research Associates of Oregon, Portland, presented data in Colorado Springs, Colo, at the First International Olympic Committee World Congress on Sports Sciences from the Athletic Injury Monitoring System that indicate knee braces do not serve to reduce injuries, nor do they lessen the severity of injuries. Zemper says that, while the concept of the prophylactic knee brace is intuitively logical, the results from the survey seem to indicate that more developmental work on prophylactic braces must be done before there will be any prospect of significant impact on injury reduction. Prophylactic knee braces are designed to protect against damage to the
Abstract 2396: Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients
Authors: Yuyan Han, Jeri Kim, Xifeng Wu, Jian Gu
Journal: Cancer Research (2017)

Abstract Background: Global DNA methylation may affect chromosome structure and genomic stability and is involved in carcinogenesis. In this study, we aimed to investigate whether methylation of pericentromeric repeat (NBL2) and subtelomeric repeat (D4Z4) in peripheral blood leukocytes was associated with the aggressiveness of prostate cancer (PCa). Methods: We measured the methylation status of different CpG sites of NBL2 and D4Z4 in 900 PCa patients via pyrosequencing after bisulfite treatment. We then used multivariate logistic regression to estimate the odds ratio (ORs) and 95% confidence intervals (CIs) for analyzing the association of NBL2 and D4Z4 methylation with the aggressiveness of PCa at diagnosis. We then analyzed the association of CpG sites with the risk of biochemical recurrence (BCR) in patients receiving radical prostatectomy or radiotherapy using a multivariate Cox proportional hazards model adjusting for age, BMI, smoking status, pack year, D’Amico risk groups, and treatments. In addition, we used the Kaplan-Meier survival function and log-rank tests to assess BCR-free survival associated with these markers. Results: There was no significant differences in the methylation level of NBL2 and D4Z4 between clinically defined aggressive and non-aggressive PCa at diagnosis. However, the methylation of subtelomeric region D4Z4 was associated with BCR, while the methylation of NBL2 was not associated with BCR. In tertile analysis, we found that patients with higher methylation of D4Z4 exhibited an increased risk of BCR in localized patients receiving definitive therapy. Because of the relatively low rate of BCR among patients, we combined the highest and second tertiles to increase statistical power. Patients in the second and third (highest) tertiles had an increased risk of BCR (HR=1.74, 95% CI, 1.14-2.65; p= 0.0096) compared to patients in the lowest tertile after adjustment of age, BMI, smoking status, pack year, D’Amico risk groups, and treatments. We assayed 4 CpG sites in this region. In detailed analysis of each CpG site, the association was mostly attributable to the methylation of the 2nd methylation site of D4Z4 (HR=1.80, 95% CI, 1.19 - 2.72). Conclusion: These data suggest that methylation in the subtelomeric region D4Z4 may be able to predict worse prognosis of localized PCa patients. Citation Format: Yuyan Han, Jeri Kim, Xifeng Wu, Jian Gu. Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2396. doi:10.1158/1538-7445.AM2017-2396
System of Diseases of the Ear, Nose, and Throat.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ACTR-01. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
Authors: Tomokazu Aoki, Yoshiki Arakawa, Tetsuya Ueba, Masashi Oda, Namiko Nishida, Yukinori Akiyama, Tetsuya Tsukahara, Koichi Iwasaki, Nobuhiro Mikuni, Susumu Miyamoto
Journal: Neuro-Oncology (2019)

Abstract The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemoregimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m2/day) (Day 1–5) plus various doses of ACNU (30, 35, 40, 45 mg/m2/day) (Day 15) per 4 weeks was defined on a standard 3 + 3 design. In phase II, these therapeutic activity and safety of this regimen were evaluated. Forty-nine eligible patients were enrolled. The median age was 50 years-old. Eighty percent had a KPS of 70–100. Histologies were glioblastoma (73%), anaplastic astrocytoma (22%), anaplastic oligodendroglioma (4%). In phase I, 15 patients were treated at four cohorts by TMZ plus ACNU. MTD was TMZ (150 mg/m2) plus ACNU (40 mg/m2). In phase II, 40 patients were treated at the dose of cohort 3 (MTD). Thirty-five percent of patients experienced grade 3 or 4 toxicities, mainly hematologic. The overall response rate was 11% (4/37). Sixty-eight percent (25/37) had stable disease. Twenty-two percent (8/37) showed progression. Progression-free survival (PFS) rates at 6 and 12 months were 24% (95% CI, 12–35%) and 8% (95% CI, 4–15%). Median PFS was 13 months (95% CI, 9.2–17.2 months). Overall survival (OS) at 6 and 12 were 78% (95% CI, 67–89%) and 49% (95% CI, 33–57%). Median OS was 11.8 months (95% CI, 8.2–14.5 months). This phase I/II study showed a moderate toxicity in hematology and may has a promising efficacy in OS, without inferiority in PFS.
Treatment of acute falciparum malaria with sulfalene and trimethoprim
Authors: D. C. Martin
Journal: JAMA (1968)

The combination of a long-acting sulfonamide, sulfalene, and a dihydrofolic acid reductase inhibitor, trimethoprim, proved to be effective as a radical cure against a normal, as well as a chloroquine-quinine-pyrimethamine-resistant<i>Plasmodium falciparum</i>in nonimmune volunteers. The malaria caused by normal<i>P falciparum</i>was cured (eight of eight cases) by sulfalene (0.25 gm) plus trimethoprim (0.125 gm) administered as a single dose. Sulfalene (0.75 gm) plus trimethoprim (0.5 gm) combined cured ten of 11 patients with malaria caused by chloroquine-pyrimethamine-quinine-resistant<i>P falciparum</i>. Attempts to induce resistance to the combination have been unsuccessful thus far. The speed of action in clearance of parasites and lysis of fever compares favorably with that of chloroquine at its best. The combination is easily tolerated as a single dose.
An Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Romiplostim in Thrombocytopenic Patients (Pts) with Myelodysplastic Syndromes (MDS).
Authors: Pierre Fenaux, Hagop Kantarjian, Roger Lyons, Richard A. Larson, Mikkael A. Sekeres, Pamela S. Becker, Petra Muus, Kuolong Hu, Dietmar Berger, Janet L. Franklin
Journal: Blood (2009)
THE MODE OF ACTION OF THE FINSEN LIGHT.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Measles Vaccine
Authors: Arlene L. Fraikor
Journal: JAMA (1975)

<h3>To the Editor.—</h3> My 12-year-old son was recently diagnosed as having measles. His medical records indicate that he received "measles vaccine" in 1963. His current pediatrician mentioned that he and his colleagues have seen several cases of measles in persons who supposedly were vaccinated. Some of these patients had even had booster immunizations. This raises some very interesting epidemiological questions. (1) Is the current form of measles caused by a single newly mutated viral strain, or (2) Do the current measles cases indicate that the patients received an ineffective vaccine? If this is the situation, how widely distributed was the ineffective batch(es)? To facilitate future epidemiological studies, it would be extremely helpful if physicians would record the following information on the patient's medical record: (1) name of vaccine, (2) company producing the vaccine, (3) date of production, and (4) lot or batch number used. Similar information might also be recorded
New leads on brain functioning: how we speak, hear, and see
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Unclear Information in Table
Journal: JAMA (2016)

Evan R. Myers, MD, MPH; Patricia Moorman, PhD; Jennifer M. Gierisch, PhD, MPH; Laura J. Havrilesky, MD, MHSc; Lars J. Grimm, MD; Sujata Ghate, MD; Brittany Davidson, MD; Ranee Chatterjee Mongtomery, MD; Matthew J. Crowley, MD; Douglas C. McCrory, MD, MHSc; Amy Kendrick, RN, MSN; Gillian D. Sanders, PhD
Decision Tables
Authors: Robert R. Holland
Journal: JAMA (1975)

A CONSTRUCTIVE approach to the information explosion can be seen in the work of Calvin Kunin, MD, on urinary tract infections (UTIs). The first edition of his book<i>Detection, Prevention, and Management of Urinary Tract Infections</i>is 200 pages long and represents the findings of 240 articles; the second edition, recently published, represents 500 articles and is 300 pages long. Realizing that it would be impossible under the time constraints of practice for everyone to either read or remember accurately the content of his book or the original articles, Dr. Kunin has, in an accompanying article, reduced the content to 0 pages and three flow charts. This was done with the expectation that the information he presents could then be used in the day-to-day practice of medicine for all patients regardless of time constraints, rather than just existing lifelessly between bookcovers. This communication presents decision tables as an alternative to
Reciprocity.
Authors: H. B. Young.
Journal: JAMA (1903)

Burlington, Iowa, Aug. 1, 1903. <i>To the Editor:</i>—About a year ago you did me the honor of publishing my views about "the one simple and practical way of getting reciprocity in the practice of medicine," namely: amendment to that effect in the medical laws of all the states. I see in the current issue of The Journal that Vermont and Oregon have just such amendments, and while I am not vain enough to suppose that my views above referred to were in any way responsible for such action, I am none the less pleased to see that other people are as little visionary about this matter as I am.
From the Centers for Disease Control and Prevention. Public health: surveillance, prevention, and control of nosocomial infections
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ulcerative Colitis
Authors: Louis Zetzel
Journal: New England Journal of Medicine (1954)

THE medical treatment of ulcerative colitis, like that of many conditions of unknown etiology, has been varied and profuse with results that are unpredictable and often unsatisfactory. Since 1875, when Wilks and Moxon1 first separated it as an entity from the larger group of specific dysenteries, many theories have been advanced regarding its cause,2 pathogenesis3 , 4 and optimum therapy,5 , 6 but no concept has withstood the scrutiny of critical study or the challenging test of time. The absence of a specific etiologic agent has made it necessary to rely on empirical measures for symptomatic control. The resources of skill and patience, fortified . . .